Terry Coelho joined Gamida Cell’s leadership team as Chief Financial Officer in May 2023, bringing more than 35 years of experience across all areas of finance to her role.

Previously she served as the Executive Vice President, Chief Financial Officer & Chief Business Development Officer of CinCor Pharma, Inc., a clinical-stage cardiorenal therapeutics company, including preparing the company for its eventual sale to AstraZeneca. Her experience also includes serving as Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a commercial-stage specialty pharmaceutical company acquired by Collegium Pharmaceuticals in 2022; Chief Financial Officer at Balchem Corporation (NASDAQ: BCPC) and at Diversey, Inc.; and in a series of senior financial and executive roles at Sealed Air Corporation, Mars, Inc. and Novartis Pharmaceuticals, where for seven years she held roles of increasing responsibility including as finance lead for the oncology hematology franchise and later leading global oncology development finance.

Terry currently serves as an independent director on the public company boards of First Wave BioPharma (Nasdaq: FWBI), HOOKIPA Pharma (Nasdaq: HOOK) and Inotiv (NASDAQ: NOTV). She is chairperson of the audit committee at First Wave BioPharma and HOOKIPA, and chairperson of the Nominating & Corporate Governance Committee at Inotiv. She is also a founding advisory board member of the CFO Leadership Council (Charlotte and Raleigh chapters). She has previously served on Northeastern University’s MBA Finance Track advisory board and the University of North Carolina Charlotte Women in Business advisory board.

Terry holds an MBA in Finance from IBMEC in Brazil and a Bachelor of Arts, summa cum laude, in Economics and International Relations from The American University School of International Service.